What was filed
Fermenta Biotech Limited told the exchanges that its existing equity shares were listed and admitted to dealings on the National Stock Exchange of India (NSE) with effect from 4 August 2026, under the symbol FERMENTA and ISIN INE225B01021. The shares continue to remain listed on the BSE under Scrip Code 506414. This is a dual listing rather than a fresh issue — no new capital was raised, and the filing concerns the admission of already-issued shares to a second exchange.
Company context from the filing
Fermenta describes itself as one of the world's largest manufacturers of Vitamin D3 API, with a portfolio spanning nutritional ingredients, green chemistry, APIs and food premixes, serving customers in more than 60 countries. The company said it was founded in 1951 and has been listed on the BSE since 1977. Managing Director Prashant Nagre said the NSE listing strengthens the company's capital-market presence and enables participation of a wider community of market participants.
Why it matters to a holder
For existing shareholders, a second listing changes where the shares can be traded, not how many exist. The company said the dual listing is expected to increase accessibility and support broader participation, improved visibility and more efficient price discovery across both major Indian exchanges. The share count and the BSE listing are unchanged by this event.